---
schema_version: "secwatch.filing_event.v1"
accession: "0001576885-23-000068"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2023-12-04T23:59:59+00:00"
generated_at: "2026-06-07T18:45:05.631247+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "medium"
source: SEC EDGAR
---

# Acumen posts updated corporate presentation with plasma biomarker data from Phase 1 INTERCEPT-AD trial

## Summary
- Updated corporate presentation posted to investor website on December 4, 2023.
- Includes plasma biomarker data from Phase 1 INTERCEPT-AD trial.
- Presentation to be used in upcoming investor conferences and communications.

## SEC filing metadata
- accession: 0001576885-23-000068
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2023-12-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000157688523000068/0001576885-23-000068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000157688523000068/abos-20231204.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001576885-23-000068
- JSON: https://secwatch.observer/filing/0001576885-23-000068.json
- Plain text: https://secwatch.observer/filing/0001576885-23-000068.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.